Neonates exposed to this drug late in the third trimester may require respiratory support, tube feeding, and/or prolonged hospitalization. A pregnancy exposure registry is available. There is inconclusive data on use of this drug in the third trimester to inform of a drug-related risk. Risk summary: Malformative risk is unlikely when given during the first trimester. Oral concentrate and solution formulations containing alcohol: Not recommended. This drug should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus, taking into account the risks of untreated depression. Do not stop using any medications without first talking to your doctor. It is important to tell your doctor about all other medications you use, including vitamins and herbs. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with these medications, whether together or alone.
Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. Talk to your doctor if you have any questions or concerns. You may be more susceptible if you have a heart condition called congenital long QT syndrome, other cardiac diseases, conduction abnormalities, or electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting). Using ARIPiprazole together with sertraline can increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening, although it is a relatively rare side effect. The following applies to the ingredients:
0 kommentar(er)
